Mesoblast (ASX: MSB) – FDA Approves Potency Assay for Ryoncil 2
Mesoblast has received FDA approval to implement a new potency assay for its approved cell therapy product Ryoncil, a regulatory milestone that...
Mesoblast has received FDA approval to implement a new potency assay for its approved cell therapy product Ryoncil, a regulatory milestone that...
Healius Limited has been placed in a trading halt effective from 24 September 2026, following a request from the company pending the release of a...
oOh!media Limited (ASX: OML) A$1.670 0.00% has cleared a significant regulatory hurdle with the Australian Competition and Consumer Commission confirming it will...
NRW Holdings' wholly owned subsidiary Fredon has secured a significant contract award for the Stack Data Centre MEL03, marking another major win in...
Premier Investments delivered FY26 results in line with guidance, posting profit before tax of $211.1 million and statutory net profit after tax of...
Soul Patts delivered a total shareholder return of 16.8% in FY26, substantially outperforming the ASX200's 6.0% return. This marked the company's...
Premier Investments reported a 10.29% decline in continuing operations profit to $129.2 million for the year ended 25 July 2026, reflecting...
Washington H. Soul Pattinson and Company Limited delivered a landmark result for FY26, with post-tax net asset value reaching $14.5 billion, a 31.4...
News Corporation announced the release of its 2026 annual report to security holders on 22 September 2026, with the filing authorized for release to...
Washington H. Soul Pattinson and Company Limited completed a transformative merger with Brickworks Limited in September 2025, creating a combined...
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000